Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post earnings of ($0.16) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.14). BioCryst Pharmaceuticals reported earnings of ($0.19) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 15.8%. The business is scheduled to announce its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($0.79) per share for the current financial year, with EPS estimates ranging from ($0.87) to ($0.68). For the next financial year, analysts expect that the firm will post earnings of ($0.78) per share, with EPS estimates ranging from ($0.83) to ($0.72). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.06). The company had revenue of $3.89 million for the quarter, compared to analysts’ expectations of $6.07 million. BioCryst Pharmaceuticals had a negative net margin of 261.18% and a negative return on equity of 106.53%. The firm’s revenue for the quarter was down 56.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) earnings per share.
A number of analysts have recently issued reports on BCRX shares. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. Barclays started coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 target price for the company. BidaskClub raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Royal Bank of Canada upgraded BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Tuesday, January 2nd. Finally, Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 5th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.29.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down $0.05 on Friday, hitting $5.33. 314,340 shares of the stock were exchanged, compared to its average volume of 1,288,833. The stock has a market capitalization of $531.49, a price-to-earnings ratio of -6.82 and a beta of 2.63. BioCryst Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $9.25. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.68 and a quick ratio of 2.53.
Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 15.0% in the fourth quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock valued at $37,386,000 after acquiring an additional 993,100 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at about $23,762,000. State Street Corp raised its holdings in shares of BioCryst Pharmaceuticals by 72.0% in the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after acquiring an additional 1,636,909 shares in the last quarter. RTW Investments LP raised its holdings in shares of BioCryst Pharmaceuticals by 1.4% in the fourth quarter. RTW Investments LP now owns 3,372,674 shares of the biotechnology company’s stock valued at $16,560,000 after acquiring an additional 47,969 shares in the last quarter. Finally, VHCP Management II LLC raised its holdings in shares of BioCryst Pharmaceuticals by 27.9% in the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock valued at $16,587,000 after acquiring an additional 690,290 shares in the last quarter. Hedge funds and other institutional investors own 91.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.16 EPS” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://ledgergazette.com/2018/03/16/brokerages-expect-biocryst-pharmaceuticals-inc-bcrx-to-announce-0-16-eps.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.